TuHURA Biosciences, Inc./NV (HURA) Form 8-K — Aug 14, 2026
TuHURA Biosciences (Nasdaq: HURA) filed an 8-K on August 14, 2026 furnishing its second quarter 2026 results, reporting cash and cash equivalents of just $1.0 million at June 30, 2026 with approximately 63.7 million common shares outstanding. Quarterly spending stepped up, with R&D expense of $6.6 million versus $4.9 million a year earlier and G&A expense of $2.1 million versus $1.9 million, while net operating cash outflows reached $13.0 million for the first six months of 2026 versus $10.9 million in the prior-year period.
Key figures
- Guidance
- No formal financial guidance; management targets 2H 2026 milestones including FDA safe-to-proceed feedback and Phase 1b/2 initiation for TBS-2025 in mutNPM1 r/r AML, potential orphan drug designations for IFx-2.0 in MCC and TBS-2025 in AML, and initiation of ADC in vivo POC studies; stated cash runway into 2028.
- Debt Amount
- $50 million committed non-convertible term credit facility from largest shareholder
- Cash Position
- $1.0 million (June 30, 2026)
- Interest Rate
- 12% annually on outstanding drawn funds
- Maturity Date
- April 21, 2031
- Shares Outstanding
- approximately 63.7 million
- Atm Gross Proceeds
- $0.3 million (April 2026) and $0.1 million (July 2026)
- Ga Expense Q2 2025
- $1.9 million
- Ga Expense Q2 2026
- $2.1 million
- Mut NPM1 Share Of AML
- approximately 35% of AML patients
- Rnd Expense Q2 2025
- $4.9 million
- Rnd Expense Q2 2026
- $6.6 million
- Financing Cash Inflow6 M 2025
- $8.1 million
- Financing Cash Inflow6 M 2026
- $10.6 million
- Operating Cash Outflow6 M 2025
- -$10.9 million
- Operating Cash Outflow6 M 2026
- -$13.0 million
- Parkview Credit Facility Drawn To Date
- $5.7 million, including $2.15 million subsequent to June 30, 2026
Price after filing
Close on the filing date to close N calendar days later (from $2.47). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.